statistiche ricercatore

PASSAMONTI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	24.156
EU - Europa	10.453
AS - Asia	7.019
SA - Sud America	896
AF - Africa	102
Continente sconosciuto - Info sul continente non disponibili	14
OC - Oceania	7
Totale	42.647

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	23.966
IT - Italia	5.580
SG - Singapore	2.170
CN - Cina	1.574
UA - Ucraina	1.566
TR - Turchia	1.031
VN - Vietnam	1.024
HK - Hong Kong	752
BR - Brasile	736
SE - Svezia	698
IE - Irlanda	613
DE - Germania	425
GB - Regno Unito	377
FI - Finlandia	350
FR - Francia	326
RU - Federazione Russa	260
CA - Canada	100
IN - India	87
MX - Messico	69
BD - Bangladesh	64
JP - Giappone	62
AR - Argentina	61
PK - Pakistan	46
CZ - Repubblica Ceca	41
NL - Olanda	40
AT - Austria	35
IQ - Iraq	34
PL - Polonia	30
EC - Ecuador	28
ES - Italia	27
ZA - Sudafrica	27
ID - Indonesia	24
SA - Arabia Saudita	22
UZ - Uzbekistan	19
VE - Venezuela	16
LT - Lituania	15
CO - Colombia	14
BE - Belgio	13
CL - Cile	13
MY - Malesia	13
EG - Egitto	11
EU - Europa	11
JO - Giordania	11
MA - Marocco	11
NG - Nigeria	11
AE - Emirati Arabi Uniti	9
DZ - Algeria	9
HU - Ungheria	9
KE - Kenya	9
KR - Corea	9
PY - Paraguay	9
IR - Iran	8
PE - Perù	8
BG - Bulgaria	7
CH - Svizzera	7
ET - Etiopia	7
KZ - Kazakistan	7
LB - Libano	7
TW - Taiwan	7
UY - Uruguay	7
IL - Israele	6
NO - Norvegia	6
NP - Nepal	6
RS - Serbia	6
TH - Thailandia	6
OM - Oman	5
SN - Senegal	5
TN - Tunisia	5
AU - Australia	4
AZ - Azerbaigian	4
BA - Bosnia-Erzegovina	4
HN - Honduras	4
PH - Filippine	4
RO - Romania	4
CR - Costa Rica	3
DO - Repubblica Dominicana	3
GR - Grecia	3
NZ - Nuova Zelanda	3
TT - Trinidad e Tobago	3
AL - Albania	2
AO - Angola	2
BO - Bolivia	2
DK - Danimarca	2
GY - Guiana	2
JM - Giamaica	2
KW - Kuwait	2
LU - Lussemburgo	2
MD - Moldavia	2
PA - Panama	2
PS - Palestinian Territory	2
SK - Slovacchia (Repubblica Slovacca)	2
XK - ???statistics.table.value.countryCode.XK???	2
A2 - ???statistics.table.value.countryCode.A2???	1
BS - Bahamas	1
BW - Botswana	1
CI - Costa d'Avorio	1
GE - Georgia	1
GT - Guatemala	1
KN - Saint Kitts e Nevis	1
LY - Libia	1
Totale	42.640

Salva come PNG Salva come JPEG

Città	#
Milan	4.206
Fairfield	3.291
Woodbridge	2.767
Houston	2.074
Ashburn	2.027
Ann Arbor	1.578
Jacksonville	1.337
San Jose	1.335
Seattle	1.332
Cambridge	1.176
Wilmington	1.124
Singapore	1.112
Hong Kong	738
Chandler	678
Dublin	610
Dallas	558
Princeton	525
Dearborn	479
Izmir	473
Nyköping	365
Boardman	337
The Dalles	315
Beijing	283
Dong Ket	271
Rome	240
Lauterbourg	235
San Diego	176
Ho Chi Minh City	160
Ogden	133
Hanoi	125
Los Angeles	104
London	98
Como	84
New York	80
Guangzhou	78
Chicago	73
Santa Clara	70
São Paulo	66
Redmond	64
Washington	64
Helsinki	61
Hefei	54
Council Bluffs	49
Mexico City	49
Orem	49
Kocaeli	48
Nanjing	45
Tokyo	45
Munich	44
Hangzhou	43
Kunming	37
Zhengzhou	36
Shanghai	35
Toronto	34
Da Nang	30
Brno	29
Kilburn	29
Norwalk	29
Rio de Janeiro	29
Tianjin	29
Montreal	27
Nuremberg	27
San Francisco	27
Frankfurt am Main	26
Warsaw	26
Brooklyn	25
Redwood City	25
Jinan	23
Atlanta	21
Chennai	21
Columbus	21
Düsseldorf	21
Nanchang	21
Haiphong	20
Ankara	19
Boston	19
Phoenix	19
Changsha	18
Denver	18
Johannesburg	18
Salt Lake City	18
Tashkent	18
Belo Horizonte	17
Rawalpindi	17
Verona	17
Poplar	16
Quito	16
Turku	16
Vienna	16
Dhaka	15
Acton	14
Amsterdam	14
Brasília	14
Chengdu	14
Manchester	14
Shenzhen	14
Biên Hòa	13
Brussels	13
Fuzhou	13
Shenyang	13
Totale	32.389

Salva come PNG Salva come JPEG

Nome	#
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm	288
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence	279
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.	264
Analysis of three screening methods for the detection of calreticulin gene mutations	264
A gain-of-function mutation of JAK2 in myeloproliferative disorders	254
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group	246
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations	243
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis	242
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis	239
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN	236
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts	235
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.	234
Mutations and thrombosis in essential thrombocythemia: Prognostic interaction with age and thrombosis history	233
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms	230
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study	229
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.	228
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.	227
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma	227
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group	223
Looking for CALR mutations in familial myeloproliferative neoplasms	220
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA	218
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion	217
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia	215
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.	215
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients	215
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis	214
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.	212
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera	211
A novel germline JAK2 mutation in familial myeloproliferative neoplasms	210
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies	209
Mutational status of myeloproliferative neoplasms.	209
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.	208
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients	206
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.	206
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.	203
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia	203
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.	202
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders	202
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms	202
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts	201
It is time to change thrombosis risk assessment for PV and ET?	199
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.	197
Developments in diagnosis and treatment of essential thrombocythemia	197
Novel agents in indolent lymphomas	196
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients	196
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project	196
Standard care and investigational drugs in the treatment of myelofibrosis	196
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group	196
Direct-Acting Antivirals During or After Immunochemotherapy in Hepatitis C Virus-Positive Diffuse Large B-Cell Lymphomas	194
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs	194
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders	193
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons	193
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.	193
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients	193
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis	193
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN.	192
Role of the molecular staging and response in the management of follicular lymphoma patients	192
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment	192
What are RBC-transfusion-dependence and -independence?	191
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.	191
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT.	191
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2	191
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial	191
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report	190
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia	190
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.	190
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	189
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)	189
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients	189
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis	189
RBC-transfusion guidelines update	188
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.	187
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients.	187
Disease anticipation in familial myeloproliferative neoplasms.	186
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study	186
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group	186
Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden	186
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy	185
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma	185
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process	184
JAK inhibitor in CALR-mutant myelofibrosis	184
How I treat polycythemia vera	184
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs	184
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis	184
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis.	183
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub	183
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.	182
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis	181
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!	181
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.	179
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis	179
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment	178
Blast phase of essential thrombocythemia: A single center study.	178
Myeloproliferative Neoplasms	178
Clinical Predictors of Outcome in MPN	178
Cardiovascular events and intensity of treatment in polycythemia vera	178
New generation small-molecule inhibitors in myeloproliferative neoplasms	177
How to manage polycythemia vera	177
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy	176
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)	176
Totale	20.262

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	168.057
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	168.057

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	1.362	0	0	0	0	0	0	0	0	0	298	438	626
2021/2022	2.587	335	436	24	118	96	128	150	159	146	416	243	336
2022/2023	2.444	283	79	141	230	177	650	15	300	372	82	40	75
2023/2024	6.571	1.015	1.045	1.030	1.308	1.278	449	66	83	201	20	24	52
2024/2025	3.136	26	12	606	106	104	251	107	217	389	241	246	831
2025/2026	8.178	591	535	640	1.179	557	496	1.744	696	1.287	453	0	0
Totale													43.182